Roberto Corinaldesi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roberto Corinaldesi has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Raffaele Pezzilli
Department of Gastroenterology, San Carlo Hospital, Potenza
20 shared publications - Roberto De Giorgio
Department of Translational Medicine, University of Ferrara, 44124 Ferrara, Italy
16 shared publications - Vincenzo Stanghellini
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
16 shared publications - Giovanni Barbara
Department of Medical and Surgical Sciences University of Bologna Bologna Italy
15 shared publications - Antonio Maria Morselli-Labate
Independent Researcher, Italy
12 shared publications - Cesare Cremon
IRCCS Azienda Ospedaliero, Universitaria di Bologna, 40138 Bologna, Italy
9 shared publications
Latest Publications
- 1 June 2014
- Published by Elsevier in Pancreatology
- Vol. 14 (3) , S6
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: a single center prospective, randomized controlled study.
- 1 June 2014
- Published by Elsevier in Pancreatology
- Vol. 14 (3) , S6
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: a single center prospective, randomized controlled study.
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
843 Mucosal Immune Biomarkers in Patients With Irritable Bowel Syndrome
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
843 Mucosal Immune Biomarkers in Patients With Irritable Bowel Syndrome
- 17 October 2012
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 7 (S3) , 255-262
Clinical approach to diarrhea
Diarrhea is defined as reduced stool consistency, increased water content and number of evacuations per day. A wide array of causes and pathophysiological mechanisms underlie acute and chronic forms of diarrhea. This review focuses on the major clinical aspects which should aid clinicians to diagnose chronic diarrhea. Clinical history, physical examination and stool evaluation and the predominant stool characteristic, i.e., bloody, watery, and fatty diarrhea, may narrow the differential diagnosis. Although mainly involved in acute diarrhea, many different infectious agents, including bacteria, viruses and protozoa, can be identified in chronic bloody/inflammatory diarrhea by appropriate microbiological tests and colonoscopic biopsy analysis. Osmotic diarrhea can be the result of malabsorption or maldigestion, with a subsequent passage of fat in the stool leading to steatorrhea. Secretory diarrhea is due to an increase of fluid secretion in the small bowel lumen, a mechanism often identified in gastroenteropancreatic neuroendocrine tumors. The evaluation of the fecal osmotic gap may help to characterize whether a chronic diarrhea is osmotic or secretory. Fatty diarrhea (steatorrhea) occurs if fecal fat output exceeds the absorptive/digestive capacity of the intestine. Steatorrhea results from malabsorption or maldigestion states and tests should differentiate between these two conditions. Individualized diagnostic work ups tailored on pathophysiological and clinical features are expected to reduce costs for patients with chronic diarrhea.
- 17 October 2012
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 7 (S3) , 255-262
Clinical approach to diarrhea
Diarrhea is defined as reduced stool consistency, increased water content and number of evacuations per day. A wide array of causes and pathophysiological mechanisms underlie acute and chronic forms of diarrhea. This review focuses on the major clinical aspects which should aid clinicians to diagnose chronic diarrhea. Clinical history, physical examination and stool evaluation and the predominant stool characteristic, i.e., bloody, watery, and fatty diarrhea, may narrow the differential diagnosis. Although mainly involved in acute diarrhea, many different infectious agents, including bacteria, viruses and protozoa, can be identified in chronic bloody/inflammatory diarrhea by appropriate microbiological tests and colonoscopic biopsy analysis. Osmotic diarrhea can be the result of malabsorption or maldigestion, with a subsequent passage of fat in the stool leading to steatorrhea. Secretory diarrhea is due to an increase of fluid secretion in the small bowel lumen, a mechanism often identified in gastroenteropancreatic neuroendocrine tumors. The evaluation of the fecal osmotic gap may help to characterize whether a chronic diarrhea is osmotic or secretory. Fatty diarrhea (steatorrhea) occurs if fecal fat output exceeds the absorptive/digestive capacity of the intestine. Steatorrhea results from malabsorption or maldigestion states and tests should differentiate between these two conditions. Individualized diagnostic work ups tailored on pathophysiological and clinical features are expected to reduce costs for patients with chronic diarrhea.
- 9 September 2011
- Vol. 12 (5) , 495-6
Early treatment of acute pancreatitis: do not forget the need for water.
- 9 September 2011
- Vol. 12 (5) , 495-6
Early treatment of acute pancreatitis: do not forget the need for water.
- 30 May 2011
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (9) , 1029-1038
Therapeutic management and clinical outcome of autoimmune pancreatitis
Autoimmune pancreatitis, in comparison to other benign chronic pancreatic diseases, is characterized by the possibility of curing the illness with immunosuppressant drugs. The open question is whether to differentiate autoimmune pancreatitis as a primary or secondary disease based on the presence or absence of other autoimmune diseases or whether to consider autoimmune pancreatitis a clinical and pathological systemic entity, called IgG4-related sclerosing disease, since this aspect is also very important from a therapeutic point of view. In this paper, we reviewed the conventional therapeutic approach used to treat autoimmune pancreatitis patients and the clinical outcome related to each treatment modality. We also reviewed some aspects which are important for the correct management of autoimmune pancreatitis, such as the surgical approach, the outcome of surgically treated autoimmune pancreatitis patients, whether medical treatment is always necessary, and, finally, when medical treatment should be initiated. Steroids are useful in alleviating the symptoms of the acute presentation of autoimmune pancreatitis, but some questions remain open such as the dosage of steroids in the acute phase and the duration of steroid therapy; finally, it should be assessed if other immunosuppressive non-steroidal drugs may become the first-line therapy in patients with AIP without jaundice and without atrophic pancreas.
- 30 May 2011
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (9) , 1029-1038
Therapeutic management and clinical outcome of autoimmune pancreatitis
Autoimmune pancreatitis, in comparison to other benign chronic pancreatic diseases, is characterized by the possibility of curing the illness with immunosuppressant drugs. The open question is whether to differentiate autoimmune pancreatitis as a primary or secondary disease based on the presence or absence of other autoimmune diseases or whether to consider autoimmune pancreatitis a clinical and pathological systemic entity, called IgG4-related sclerosing disease, since this aspect is also very important from a therapeutic point of view. In this paper, we reviewed the conventional therapeutic approach used to treat autoimmune pancreatitis patients and the clinical outcome related to each treatment modality. We also reviewed some aspects which are important for the correct management of autoimmune pancreatitis, such as the surgical approach, the outcome of surgically treated autoimmune pancreatitis patients, whether medical treatment is always necessary, and, finally, when medical treatment should be initiated. Steroids are useful in alleviating the symptoms of the acute presentation of autoimmune pancreatitis, but some questions remain open such as the dosage of steroids in the acute phase and the duration of steroid therapy; finally, it should be assessed if other immunosuppressive non-steroidal drugs may become the first-line therapy in patients with AIP without jaundice and without atrophic pancreas.
- 6 May 2011
- Vol. 12 (3) , 309-10
The effect of pathological types of intraductal papillary mucinous neoplasms of the pancreas on survival.
- 6 May 2011
- Vol. 12 (3) , 309-10
The effect of pathological types of intraductal papillary mucinous neoplasms of the pancreas on survival.
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Mucosal Neuroplasticity and Its Correlation With Symptoms in Patients With Irritable Bowel Syndrome
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Mucosal Neuroplasticity and Its Correlation With Symptoms in Patients With Irritable Bowel Syndrome
- 1 April 2011
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 10 (2) , 191-195
Is the pancreas affected in patients with septic shock? — a prospective study
- 1 April 2011
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 10 (2) , 191-195
Is the pancreas affected in patients with septic shock? — a prospective study